Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

Sponsors

Lead Sponsor: Brigham and Women's Hospital

Collaborator: Icahn School of Medicine at Mount Sinai
Montefiore Medical Center
Baylor College of Medicine
Baylor Health Care System
Beth Israel Deaconess Medical Center
University of Colorado, Denver
Cook County Hospital
The Cooper Health System
Duke University
Georgetown University
Hackensack mountainside hospital
Hackensack Meridian Health
Indiana University Health Methodist Hospital
Johns Hopkins University
Loma Linda University
Mayo Clinic
Medical College of Wisconsin
Northwestern
Weill Medical College of Cornell University
NYU Langone Health
Ochsner Health System
Oregon Health and Science University
Renown Health
Rush University Medical Center
New Jersey Medical School
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
Stanford University
Temple University
Tufts Medical Center
Tulane University
University of California, Davis
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of North Carolina, Chapel Hill
University Hospitals Cleveland Medical Center
University Medical Center of Southern Nevada
University of Alabama at Birmingham
University of Chicago
University of Florida
University of Illinois at Chicago
University of Kentucky
University of Miami
University of Michigan
University of Oklahoma
University of Pennsylvania
University of Pittsburgh Medical Center
University of Tennessee Health Science Center
University of Washington
University of Texas, Southwestern Medical Center at Dallas
Yale University

Source Brigham and Women's Hospital
Brief Summary

Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.

Detailed Description

The goals of this project are to determine the independent risk factors for hospital mortality and acute organ injury, and to identify treatment strategies associated with improved survival. Additionally, we will assess outcomes according to differences in geographic and institutional parameters.

Overall Status Active, not recruiting
Start Date 2020-04-01
Completion Date 2022-08-01
Primary Completion Date 2020-08-01
Study Type Observational
Primary Outcome
Measure Time Frame
28-Day Mortality 28-days from the day of ICU admission
Secondary Outcome
Measure Time Frame
60-Day Mortality 60-days from the day of ICU admission
90-Day Mortality 90-days from the day of ICU admission
Enrollment 5154
Condition
Intervention

Intervention Type: Other

Intervention Name: No intervention

Description: Observational

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria (each of the following): 1. Adults (aged ≥18 years) 2. Laboratory-confirmed diagnosis of COVID-19 3. Hospitalized in the ICU for illness related to COVID-19 Exclusion Criteria: -None

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Location
Facility: Brigham and Women's Hospital
Location Countries

United States

Verification Date

2021-05-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Brigham and Women's Hospital

Investigator Full Name: David Leaf

Investigator Title: Assistant Professor of Medicine, Harvard Medical School

Has Expanded Access No
Condition Browse
Acronym STOP-COVID
Study Design Info

Observational Model: Cohort

Time Perspective: Other

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News